Identification of Biomarkers, New Treatments, and Vaccines for COVID-19

lt;b>Dr. Paul C. Guest, Ph.D, is a scientific researcher/writer with 38 years of experience in the fields of metabolic and neurological disorders. This includes experience in both academia and the pharmaceutical industry with the majority of time spent at the University of Cambridge and Merck Sharp & Dohme in the United Kingdom. He has also been affiliated with the University of Campinas in Sao Paulo Brazil since 2015, still focused on advancing the field of biomarkers for neurological disorders such as schizophrenia and age-related diseases such as diabetes, cancer, cardiovascular disorders, sarcopenia and Alzheimer's disease. 

1. Genetic Aspects and Immune Responses in Covid-19: Important Organ Involvement.- 2. Prevalence of COVID-19 and the Continued Citizen-based Control in Japan.- 3. COVID-19 Pandemicin Brazil: History, Characteristics, and Evolution.- 4.     The Experiences of Recovered COVID-19 Patients in Baqiyatallah Hospital: A Qualitative Study.- 5.     Age-specific Differences in the Severity of COVID-19 Between Children and Adults: Reality and Reasons.- 6.     Sex differences and COVID-19.- 7.     Intestinal Microbiota in the Sars-Cov2 Infection: What is known?.- 8.     SARS-CoV-2 Infection and the Kidneys: an Evolving Picture.- 9.     Cutaneous Manifestations of COVID-19: Early Diagnosis and Prognostic Information.- 10.  How do we Manage Breastfeeding during the COVID-19 Pandemic?.- 11.  Deep Learning Analysis in Prediction of COVID-19 Infection Status using Chest CT Scan Features.- 12.  Using Ozone Therapy as an Option for Treatment of COVID-19 Patients: A Scoping Review.- 13.  COVID-19, Coenzyme Q10 and Selenium.- 14.  Topical Oral and Intranasal Antiviral Agents for Coronavirus Disease 2019 (COVID-19).- 15.  Cinnamon: A Promising Natural Product against COVID-19.- 16.  Curcumin and Piperine in COVID-19: a Promising Duo to the Rescue.- 17.  Association of in-hospital use of statins, aspirin and renin-angiotensin-aldosterone inhibitors with mortality and ICU admission due to COVID-19A.- 18.  The Worldwide Effort to Develop Vaccines for COVID-19.